JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB318036

Alexa Fluor® 594 Anti-Myosin light chain kinase/MLCK 抗体 [EP1458Y]

Alexa Fluor® 594 Anti-Myosin light chain kinase/MLCK antibody [EP1458Y]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal Myosin light chain kinase/MLCK antibody - conjugated to Alexa Fluor® 594.

別名を表示する

MLCK, MLCK1, MYLK1, MYLK, smMLCK, Kinase-related protein, Telokin, KRP

関連する標識済み抗体及び組成の異なる製品 (8)

  • 578 PE

    PE Anti-Myosin light chain kinase/MLCK antibody [EP1458Y]

  • 660 APC

    APC Anti-Myosin light chain kinase/MLCK antibody [EP1458Y]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-Myosin light chain kinase/MLCK antibody [EP1458Y]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-Myosin light chain kinase/MLCK antibody [EP1458Y]

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-Myosin light chain kinase/MLCK antibody [EP1458Y]

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-Myosin light chain kinase/MLCK antibody [EP1458Y]

  • Unconjugated

    Anti-Myosin light chain kinase/MLCK antibody [EP1458Y]

  • Carrier free

    Anti-Myosin light chain kinase/MLCK antibody [EP1458Y] - BSA and Azide free

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EP1458Y

アイソタイプ

IgG

標識

Alexa Fluor® 594

励起波長/蛍光波長

Ex: 590nm, Em: 617nm

キャリアフリー

No

アプリケーション

Antibody Labelling, Target Binding Affinity

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

製品の詳細

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle|Store in the dark

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

Myosin light chain kinase also known as MLCK is an enzyme that phosphorylates myosin light chain proteins facilitating muscle contraction. This kinase primarily interacts with myosin a molecular motor protein responsible for converting chemical energy into mechanical force. The myosin light chains are a part of this complex and are important for regulating myosin's ATPase activity. The molecular weight of MLCK is approximately 130 kDa. It is expressed in various tissues including smooth muscle skeletal muscle and endothelial cells reflecting its central role in these muscle types.
Biological function summary

Myosin light chain kinase plays a critical role in the regulation of muscle contraction and cellular motility. By phosphorylating the myosin light chain MLCK allows the interaction of actin and myosin which is essential for muscle contraction and movement. In smooth muscle MLCK activity is important for regulating vascular tone and blood pressure. As part of a complex with calmodulin MLCK activation depends on calcium levels linking its activity with intracellular signaling pathways influenced by calcium ions.

Pathways

Myosin light chain kinase is an integral part of the calcium-calmodulin pathway where it acts in response to increased intracellular calcium levels signaled through various cellular activities. This kinase is also involved in the RhoA-Rho kinase pathway which regulates smooth muscle contraction and cytoskeletal dynamics. Related proteins in these pathways include calmodulin whose binding activates MLCK and RhoA a small GTPase associated with the assembly of actin-myosin filaments.

Myosin light chain kinase has links to cardiovascular diseases such as hypertension due to its role in smooth muscle contraction and blood vessel function. Asthma is another condition related to MLCK as the kinase influences airway smooth muscle tone which can affect breathing. Dysregulation of MLCK activity can manifest in altered muscle contractility in these diseases making it a potential target for therapeutic intervention. Research continues to explore the kinase's interactions with calmodulin and other proteins within these disease pathways.

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Calcium/calmodulin-dependent myosin light chain kinase implicated in smooth muscle contraction via phosphorylation of myosin light chains (MLC). Also regulates actin-myosin interaction through a non-kinase activity. Phosphorylates PTK2B/PYK2 and myosin light-chains. Involved in the inflammatory response (e.g. apoptosis, vascular permeability, leukocyte diapedesis), cell motility and morphology, airway hyperreactivity and other activities relevant to asthma. Required for tonic airway smooth muscle contraction that is necessary for physiological and asthmatic airway resistance. Necessary for gastrointestinal motility. Implicated in the regulation of endothelial as well as vascular permeability, probably via the regulation of cytoskeletal rearrangements. In the nervous system it has been shown to control the growth initiation of astrocytic processes in culture and to participate in transmitter release at synapses formed between cultured sympathetic ganglion cells. Critical participant in signaling sequences that result in fibroblast apoptosis. Plays a role in the regulation of epithelial cell survival. Required for epithelial wound healing, especially during actomyosin ring contraction during purse-string wound closure. Mediates RhoA-dependent membrane blebbing. Triggers TRPC5 channel activity in a calcium-dependent signaling, by inducing its subcellular localization at the plasma membrane. Promotes cell migration (including tumor cells) and tumor metastasis. PTK2B/PYK2 activation by phosphorylation mediates ITGB2 activation and is thus essential to trigger neutrophil transmigration during acute lung injury (ALI). May regulate optic nerve head astrocyte migration. Probably involved in mitotic cytoskeletal regulation. Regulates tight junction probably by modulating ZO-1 exchange in the perijunctional actomyosin ring. Mediates burn-induced microvascular barrier injury; triggers endothelial contraction in the development of microvascular hyperpermeability by phosphorylating MLC. Essential for intestinal barrier dysfunction. Mediates Giardia spp.-mediated reduced epithelial barrier function during giardiasis intestinal infection via reorganization of cytoskeletal F-actin and tight junctional ZO-1. Necessary for hypotonicity-induced Ca(2+) entry and subsequent activation of volume-sensitive organic osmolyte/anion channels (VSOAC) in cervical cancer cells. Responsible for high proliferative ability of breast cancer cells through anti-apoptosis.
See full target information MYLK

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com